# Akums Drugs & Pharmaceuticals share price today (Akums Drugs & Pharmaceuticals Ltd, NSE: AKUMS)

> Akums Drugs & Pharmaceuticals share price today: ₹751.50 at the NSE close on 4 November 2026, up 65.8% in a year. Akums Drugs & Pharmaceuticals (NSE: AKUMS) is worth ₹11,824 crore, trades at a P/E of 38.8 and has closed between ₹420.00 and ₹819.55 over the past 52 weeks. > Akums Drugs & Pharmaceuticals Ltd's share price has risen faster than its earnings: +65.8% in a year, against −24.6% for earnings per share. AKUMS · Pharma - Formulators · data as of 4 November 2026. Page: https://www.sectoralpha.in/stocks/akums-drugs-pharmaceuticals-ltd

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: ₹751.50 (+65.8% in a year)
- P/E: 38.8× (higher than 73% of the last 1 year)
- Revenue (Jun 2026): ₹1,167 Cr (+14.0% on a year ago)
- Profit (Jun 2026): ₹101 Cr (+55.4% on a year ago)
- Operating margin: 15.0% (+2.0 points on a year ago)
- ROCE: 15%, FY26

The main question: the share price moved +65.8% in a year while yearly earnings per share moved −24.6%. The difference came from the market paying a higher multiple. ## What is the Akums Drugs & Pharmaceuticals share price today? Akums Drugs & Pharmaceuticals Ltd's share price was ₹751.50 at the close on 4 November 2026. It has been rising for 28 weeks. That is 16.8% above its average price over the last 200 trading days. Over the past 13 weeks it has done better than the NIFTY 500, and it has stayed ahead for 46 weeks in a row. In the last 52 weeks it traded between ₹420 and ₹820, and at that close it sat 83% of the way up from that low. Over the last 2.2 years the share price moved −6% while the NIFTY 500 moved −3%, so it is behind the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What changed at Akums Drugs & Pharmaceuticals this quarter? Three changes stood out: best operating margin in 13 quarters, foreign funds (FIIs) raised their stake for 3 quarters in a row and indian funds and insurers (DIIs) cut their stake for 3 quarters in a row. 1. Best operating margin in 13 quarters Operating margin was 15% in the June 2026 quarter, against 13% a year earlier. Why: The margin rose because the contract manufacturing business did more work, prices for its bulk drug ingredients recovered, and its factories were busier. Next results: check whether the contract manufacturing business keeps growing at the fast pace management expects in the September quarter. From the earnings call on 10 Aug 2026. 2. Foreign funds (FIIs) raised their stake for 3 quarters in a row From 1.1% to 4.5% of the company by the September 2026 quarter. 3. Indian funds and insurers (DIIs) cut their stake for 3 quarters in a row From 14.4% to 11.1% of the company by the September 2026 quarter. ## What are Akums Drugs & Pharmaceuticals' latest quarterly results? For April to June 2026 (the quarter ended 30 June 2026), Akums Drugs & Pharmaceuticals reported revenue of ₹1,167 crore, up 14.0% from ₹1,024 crore a year earlier, and a profit of ₹101 crore, up 55.4% from ₹65.0 crore. ### Akums Drugs & Pharmaceuticals results: April to June 2026 against a year earlier

| Measure | April to June 2026 | April to June 2025 | Change |
| --- | --- | --- | --- |
| Revenue | ₹1,167 crore | ₹1,024 crore | +14.0% |
| Profit | ₹101 crore | ₹65.0 crore | +55.4% |
| Earnings per share | ₹6.35 | ₹4.03 | +57.6% |
| Operating margin | 15.0% | 13.0% | +2.0 points |

The next results, for July to September 2026, are due by 14 November 2026: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter). Akums Drugs & Pharmaceuticals' management discussed these results on a call held on 10 August 2026; what it said is further down this page. (From the company's reported quarterly results (quarter ended 30 June 2026). Revenue and profit in ₹ crore.)

## What is the Akums Drugs & Pharmaceuticals share price history? Akums Drugs & Pharmaceuticals closed at ₹751.50 on 4 November 2026, up 65.8% from ₹453.35 a year earlier (7 November 2025). Its highest weekly close since August 2024 was ₹1,066.65 on 16 August 2024. ### Akums Drugs & Pharmaceuticals share price: then and now

| When | Close | Change to 4 Nov 2026 |
| --- | --- | --- |
| 1 week ago · 30 Oct 2026 | ₹731.70 | +2.7% |
| 1 month ago · 1 Oct 2026 | ₹813.10 | −7.6% |
| 6 months ago · 8 May 2026 | ₹557.10 | +34.9% |
| 1 year ago · 7 Nov 2025 | ₹453.35 | +65.8% |
| Earliest weekly close in our records · 9 Aug 2024 | ₹803.15 | −6.4% |
| Highest weekly close since August 2024 · 16 Aug 2024 | ₹1,066.65 | −29.5% |
| Lowest weekly close since August 2024, also the 52-week low · 5 Dec 2025 | ₹420.00 | +78.9% |
| 52-week high (weekly close) · 25 Sep 2026 | ₹819.55 | −8.3% |

Weekly closing prices. Each change is the move from that price to the 4 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes. (125 weekly closes from 9 August 2024 to 4 November 2026.)

## What is the latest news on Akums Drugs & Pharmaceuticals? 4 Nov 2026: Akums Drugs & Pharmaceuticals closed at ₹751.50, up 2.7% on the week and down 7.6% on the month. 10 Aug 2026: Akums Drugs & Pharmaceuticals held its results call for April to June 2026. Management guided: CDMO volume growth at least in the high teens in Q2; overall company volume growth at least double digit in coming quarters. ### Earlier

- 3 Jul 2026: ex-date for a dividend + special dividend of ₹3 a share. - Results for April to June 2026: Revenue up 14.0% and profit up 55.4% on a year earlier. ## What dividend does Akums Drugs & Pharmaceuticals pay? Akums Drugs & Pharmaceuticals paid ₹1 a share in regular dividends in the 12 months to 5 November 2026 (1 payment), a yield of 0.13% at the ₹751.50 close on 4 November 2026. The last was a dividend + special dividend of ₹3 a share, ex-date 3 July 2026. ### Akums Drugs & Pharmaceuticals dividends since 1 April 2021

| Ex-date | Dividend per share | Type |
| --- | --- | --- |
| 3 Jul 2026 | ₹3 | Dividend + Special |

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date. The record date is the same day as the ex-date for every payment here. 0 of 5 Of the last 5 financial years, years with an NSE dividend record

₹2 Special dividends, last 12 months

Yes. Akums Drugs & Pharmaceuticals Ltd paid out 18% of its profit as dividends in FY26, and it paid a dividend in 1 of its last 9 reported years. (From the NSE corporate-actions record, read 5 November 2026.)

## What did Akums Drugs & Pharmaceuticals management say on the latest results call? On the call for April to June 2026, held on 10 August 2026, Akums Drugs & Pharmaceuticals' management guided: CDMO volume growth at least in the high teens in Q2; overall company volume growth at least double digit in coming quarters. > “At this point, it is not a question of whether we make a U-turn from here. It is about how we improve profitability and scale this business into a profitable venture.”
> Sahil Maheshwari, on the call for April to June 2026

### What management guided

- CDMO FY27 operating margin expected in the 14-15% range; Q1 strength supports leaning toward the upper bracket. - Branded formulations expected to return to growth in later quarters, with domestic performance improving after field-force expansion. - Zambia to deliver $25 million, roughly ₹240 crore, in FY27 and similarly next financial year; Europe starts next financial year. - Zambia and Europe operating margin expected similar to or slightly above current CRAMS high-teens levels. Management’s own plans and goals, from our notes of the call. A plan is not a result. Source: [the call transcript](https://files.tijorifinance.com/insight/india/57896/Conference Call/CC-Aug26.pdf). (From the call for April to June 2026, 10 August 2026.)

## What to watch in Akums Drugs & Pharmaceuticals' next results? When Akums Drugs & Pharmaceuticals reports July to September 2026, these are the 3 checks that show whether the story is still on course. First: Zambia revenue recognition - check initial supply start, agreed government volumes and pricing, and early margin contribution. - What to check (from the call)
- Zambia revenue recognition - check initial supply start, agreed government volumes and pricing, and early margin contribution. - API operating profit trajectory toward monthly breakeven - check whether loss reduction continues without seasonality. - Oriflame manufacturing acquisition - check closing, integration milestones and initial skincare or cosmetics contribution. ## Which stock lists is Akums Drugs & Pharmaceuticals on? Akums Drugs & Pharmaceuticals is on 2 of our India lists: Momentum stocks and Pharma stocks. - [Momentum stocks Market cap cr: 11828.653136531364](https://www.sectoralpha.in/momentum-stocks-india)
- [Pharma stocks Market value (₹ crore): 11828.653136531364](https://www.sectoralpha.in/sectors/pharma-stocks-india)

## Is Akums Drugs & Pharmaceuticals profitable? Akums Drugs & Pharmaceuticals Ltd earned ₹101 Cr of net profit in the Jun 2026 quarter, +55.4% on the same quarter a year earlier. Full-year FY26 profit was ₹256 Cr. Over 11 years profit has grown 17.6% a year on average. That is 8.7% of the quarter's revenue. The same quarter a year earlier earned ₹65.0 Cr. 1 of the last 12 reported quarters were loss-making. For the full year, FY26 profit was ₹256 Cr (−25.6% on the year before). Why profit moved: revenue changed +14.0% on a year earlier and the margin moved +2.0 percentage points. Most of the change came from keeping more of each sale. On average over the last four quarters, profit changed −5.8% and revenue +9.3%. Profit is growing slower than sales: rising costs are taking part of the growth. ## How much revenue does Akums Drugs & Pharmaceuticals make, and is it growing? Akums Drugs & Pharmaceuticals Ltd reported ₹1,167 Cr of revenue in the Jun 2026 quarter, +14.0% on the same quarter a year earlier. That is the 3rd quarter in a row with growth on the year before. Over 11 years it has grown 10.4% a year on average. The last full year, FY26, came in at ₹4,359 Cr. The last four reported quarters add to ₹4,503 Cr. FY26 revenue was ₹4,359 Cr, +5.9% on the year before. Recent pace: the last four quarters grew +9.3% on average, against 10.4% a year over the longer run, so this year is growing slower than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +9.2%, against +3.2% a year over the last 8 quarters (accelerating); profit over the last 12 months grew −15.8%, against +8.3% a year (rolling over). ## How much of every ₹100 of sales does Akums Drugs & Pharmaceuticals keep? Akums Drugs & Pharmaceuticals Ltd's operating margin was 15.0% in the Jun 2026 quarter, 2.0 percentage points higher than the same quarter a year ago. Its latest full-year margin is the highest it has ever reported. Across 9 years it has been between −2.4% and 12.0%. The latest quarter is above every full year in that period. Why the margin moved: operating margin changed +2.4 percentage points on the year while gross margin changed +1.5 points. So the gain came mostly from the gross margin, which means input costs and prices charged. When margins are at a record, every ratio built on profit looks better than usual, so watch whether they hold. ## Is Akums Drugs & Pharmaceuticals' profit turning into cash? Over the last 3 years, 357% of Akums Drugs & Pharmaceuticals Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹1,181 Cr of operating cash against ₹256 Cr of profit. After ₹228 Cr of spending on assets, ₹953 Cr was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why 357% of profit came in as cash: the cash cycle stayed about the same between FY21 and FY26, so the cash follows profit, not the cycle. What to look at next: the bigger use of cash is spending on new assets, at 2.0× depreciation over three years. The next section checks what that spending is building. ## Where does Akums Drugs & Pharmaceuticals' cash go? Akums Drugs & Pharmaceuticals Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 89 days in FY26, down from 90 days in FY21. It spent ₹867 Cr on assets over the last 3 years. Customers take 67 days to pay, and stock sits for 110 days on average. At FY26 sales of ₹4,359 Cr, each day of that cycle ties up about ₹11.9 Cr, so roughly ₹1,063 Cr is tied up in the business at any time. FY26: customers took 67 days to pay and stock sat for 110 days, about 3.6 months of sales sitting as stock, for a full cycle of 89 days, shorter than FY21's 90. The full loop: cash goes out to suppliers and production on day 0. Stock sits for 110 days. Customers pay about 67 days after that. Suppliers are paid at 87 days. Together that makes the 89-day cycle. Spending on assets: ₹867 Cr over the last 3 years, against ₹434 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹177 Cr (FY26): assets paid for that are not earning yet. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is Akums Drugs & Pharmaceuticals' P/E ratio, and how does it compare with its own history? Akums Drugs & Pharmaceuticals Ltd's P/E is 38.8×, near the high end of its own history: higher than 73% of past readings. Its usual P/E (the middle reading) is 27.2×, over 1 year of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. The P/E here, and its history, use a profit figure that can leave out one-off items, so it can differ from a P/E worked out on the quarterly results. Those results' earnings per share for the four quarters to Jun 2026 add up to ₹18.53. Why the multiple is where it is: over the past year earnings per share moved −24.6% while the price moved +65.8%. The price did better than earnings, which pushed the multiple up within its own range. In short: the multiple is high against its own past, so the earnings trend underneath matters more than the multiple. The PEG ratio and its quarterly curve, which only the second data source has, are not shown on this page: its two data sources disagree by up to 4.7% on reported income across 13 comparable periods. When two sources disagree on a figure, we leave it out on purpose. The gap is a choice, not missing data. ## Is the Akums Drugs & Pharmaceuticals business getting better or worse? Akums Drugs & Pharmaceuticals Ltd's business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 9 quarters of 2 measures, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result. The return figures here are yearly, not quarterly. They show level and direction only; they can support the growth lines but never decide the reading alone. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does Akums Drugs & Pharmaceuticals earn on its capital? Akums Drugs & Pharmaceuticals Ltd earned a ROCE of 15% in FY26. That is up from a low of −16% in FY22. We cannot compare its return on capital used with its cost of capital from the data we have. It comes from a 5.9% net margin and 0.80× asset turnover (sales divided by assets). Why the return is what it is (FY26): a 5.9% net margin × 0.80× asset turnover × 1.64× leverage (assets divided by equity) ≈ 7.7% on equity. The margin does its share; borrowing is a big part of it. The quarterly return lines and the return-on-capital-used (ROIC) line, which only the second data source has, are not shown on this page: its two data sources disagree by up to 4.7% on reported income across 13 comparable periods. When two sources disagree on a figure, we leave it out on purpose. The gap is a choice, not missing data. ## Does Akums Drugs & Pharmaceuticals have too much debt? Akums Drugs & Pharmaceuticals Ltd had ₹157 Cr of borrowings against ₹3,314 Cr of equity in FY26, so its debt is 0.05× its equity. Its operating profit is 6 times its interest bill. Over 5 years borrowings went from ₹130 Cr to ₹157 Cr. Over the last 3 of those years it spent ₹867 Cr on assets. Part of the spending on assets is being paid for with borrowed money. The total-debt and debt-to-equity series, which only the second data source has, are not shown on this page: its two data sources disagree by up to 4.7% on reported income across 13 comparable periods. When two sources disagree on a figure, we leave it out on purpose. The gap is a choice, not missing data. ## What is the Akums Drugs & Pharmaceuticals shareholding pattern? Domestic institutions raised their stake in Akums Drugs & Pharmaceuticals Ltd by 3.6 percentage points over 8 quarters, the biggest change among its owners. Domestic institutions now own 11.1% of the company. Foreign institutions moved −2.8 points over the same period, to 4.5%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings. Over the last two years: Domestic institutions: +3.6 points over 8 quarters, to 11.1%; Foreign institutions: −2.8 points over 8 quarters, to 4.5%; Promoters: +0.0 points over 8 quarters, to 75.3%. Why the owners changed: foreign institutions moved −2.8 points and domestic institutions +3.6 points over 8 quarters, while promoters stayed about the same. One group of institutions took over shares from the other; it is not a change of mind by the people running the company. ## How far is Akums Drugs & Pharmaceuticals from balance-sheet trouble? For Akums Drugs & Pharmaceuticals Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date. ## How does Akums Drugs & Pharmaceuticals rank in its industry? 50.9 out of 100, rank 22 of 44 in Pharma - Formulators, with 71% of the evidence available. Akums Drugs & Pharmaceuticals Ltd scores 50.9 out of 100 against the 44 companies it is compared with in Pharma - Formulators, ranking 22. Relative strength against the index is 34.1%, and revenue and profit growth are weak. The four parts add up to the total exactly: 13.5 + 10.9 + 9.8 + 16.7 = 50.9. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Akums Drugs & Pharmaceuticals compared with? Akums Drugs & Pharmaceuticals ranks 22 of 44 Pharma - Formulators companies on the 4-Factor Sector Score, with 50.9 out of 100. 1. [Rubicon Research Ltd](https://www.sectoralpha.in/stocks/rubicon-research-ltd) RUBICON · leader · Most evidence points up · 83% evidence 71.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 30.1/35 · Revenue 46.8% · Profit 91.4% · Operating margin change 2 points · 88% evidence Capital efficiency 18.6/25 · ROCE 28.4% · Operating margin 24% · 100% evidence Valuation 6.2/20 · P/E 92.5× · PEG 2.31 · 65% evidence Relative strength 16.5/20 · Lead over its industry 28.1% · Lead over NIFTY 500 53.6% · 1 year 160.5% · 70% evidence · 11 of 12 weeks ahead Exact sum: 30.1 + 18.6 + 6.2 + 16.5 = 71.4 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 2. [Kwality Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/kwality-pharmaceuticals-ltd) KPL · breaking out · Most evidence points up · 81% evidence 71.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 29.9/35 · Revenue 37.9% · Profit 88.4% · Operating margin change 3 points · 88% evidence Capital efficiency 18.0/25 · ROCE 24.1% · Operating margin 25% · 100% evidence Valuation 11.0/20 · P/E 44.2× · PEG 0.54 · 100% evidence Relative strength 12.3/20 · Lead over its industry n/a · Lead over NIFTY 500 74.4% · 1 year 288.9% · 25% evidence · 9 of 9 weeks ahead Exact sum: 29.9 + 18 + 11 + 12.3 = 71.2 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 3. [Accent Microcell Ltd](https://www.sectoralpha.in/stocks/accent-microcell-ltd) ACCENTMIC · leader · Most evidence points up · 65% evidence 70.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.4/35 · Revenue n/a · Profit n/a · Operating margin change 7 points · 27% evidence Capital efficiency 21.5/25 · ROCE 24.9% · Operating margin 24% · 100% evidence Valuation 9.1/20 · P/E 26.9× · PEG n/a · 50% evidence Relative strength 18.6/20 · Lead over its industry 21.4% · Lead over NIFTY 500 47.6% · 1 year 132.1% · 100% evidence · 12 of 12 weeks ahead Exact sum: 21.4 + 21.5 + 9.1 + 18.6 = 70.6 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 4. [Glenmark Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/glenmark-pharmaceuticals-ltd) GLENMARK · breaking out · Most evidence points up · 86% evidence 69.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 29.1/35 · Revenue 32.9% · Profit 100% · Operating margin change 2 points · 88% evidence Capital efficiency 20.4/25 · ROCE 39.8% · Operating margin 20% · 100% evidence Valuation 11.2/20 · P/E 20.8× · PEG n/a · 50% evidence Relative strength 8.6/20 · Lead over its industry -11.4% · Lead over NIFTY 500 10.8% · 1 year 21.5% · 100% evidence · 9 of 12 weeks ahead Exact sum: 29.1 + 20.4 + 11.2 + 8.6 = 69.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 5. [Ajanta Pharma Ltd](https://www.sectoralpha.in/stocks/ajanta-pharma-ltd) AJANTPHARM · leader · Most evidence points up · 100% evidence 69.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 30.3/35 · Revenue 25% · Profit 29.8% · Operating margin change 7 points · 100% evidence Capital efficiency 21.1/25 · ROCE 34.5% · Operating margin 31% · 100% evidence Valuation 7.1/20 · P/E 34.7× · PEG 1.77 · 100% evidence Relative strength 10.5/20 · Lead over its industry -3.5% · Lead over NIFTY 500 20% · 1 year 42.3% · 100% evidence · 11 of 12 weeks ahead Exact sum: 30.3 + 21.1 + 7.1 + 10.5 = 69 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [Bliss GVS Pharma Ltd](https://www.sectoralpha.in/stocks/bliss-gvs-pharma-ltd) BLISSGVS · leader · Most evidence points up · 82% evidence 67.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 29.3/35 · Revenue 25% · Profit 43.1% · Operating margin change 8 points · 95% evidence Capital efficiency 14.7/25 · ROCE 16.9% · Operating margin 26% · 76% evidence Valuation 6.4/20 · P/E 42.4× · PEG n/a · 50% evidence Relative strength 16.7/20 · Lead over its industry 59% · Lead over NIFTY 500 86.2% · 1 year 312.8% · 100% evidence · 12 of 12 weeks ahead Exact sum: 29.3 + 14.7 + 6.4 + 16.7 = 67.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 7. [Lupin Ltd](https://www.sectoralpha.in/stocks/lupin-ltd) LUPIN · quiet · Most evidence points up · 89% evidence 66.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 27.9/35 · Revenue 28.2% · Profit 49.2% · Operating margin change 2 points · 88% evidence Capital efficiency 20.4/25 · ROCE 29.9% · Operating margin 30% · 100% evidence Valuation 16.1/20 · P/E 15.4× · PEG 0.54 · 65% evidence Relative strength 2.0/20 · Lead over its industry -24.5% · Lead over NIFTY 500 -4.7% · 1 year 2.4% · 100% evidence · 0 of 12 weeks ahead Exact sum: 27.9 + 20.4 + 16.1 + 2 = 66.4 · What this means: Earnings are strong; relative strength in its sector is -24.5% and the one-year return is 2.4%. 8. [Fredun Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/fredun-pharmaceuticals-ltd) FREDUN · breaking out · Most evidence points up · 76% evidence 65.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 31.9/43.75 · Revenue 50.3% · Profit 91.3% · Operating margin change 0 points · 88% evidence Capital efficiency 19.0/31.25 · ROCE 21.5% · Operating margin 14% · 100% evidence Valuation 14.9/25 · P/E 52.7× · PEG 0.77 · 100% evidence Relative strength: no reading this week · its 20 points are shared across the other three Exact sum: 31.9 + 19 + 14.9 = 65.8 (no relative-strength reading this week; its 20 points are shared across the other three) · What this means: There is no relative-strength reading for this week, so the score is built from earnings, capital efficiency and valuation alone. 9. [Ipca Laboratories Ltd](https://www.sectoralpha.in/stocks/ipca-laboratories-ltd) IPCALAB · turning · Most evidence points up · 78% evidence 65.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.0/35 · Revenue 10.6% · Profit 68% · Operating margin change 6 points · 83% evidence Capital efficiency 15.7/25 · ROCE 17% · Operating margin 24% · 76% evidence Valuation 11.0/20 · P/E 35.6× · PEG n/a · 50% evidence Relative strength 14.7/20 · Lead over its industry -0.5% · Lead over NIFTY 500 23.6% · 1 year 51.7% · 100% evidence · 10 of 12 weeks ahead Exact sum: 24 + 15.7 + 11 + 14.7 = 65.4 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 10. [Marksans Pharma Ltd](https://www.sectoralpha.in/stocks/marksans-pharma-ltd) MARKSANS · leader · Most evidence points up · 74% evidence 65.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 28.7/35 · Revenue 19.6% · Profit 48% · Operating margin change 9 points · 88% evidence Capital efficiency 18.3/25 · ROCE 18.8% · Operating margin 25% · 100% evidence Valuation 6.3/20 · P/E 26.8× · PEG 2.85 · 65% evidence Relative strength 11.9/20 · Lead over its industry n/a · Lead over NIFTY 500 40.1% · 1 year 68.4% · 25% evidence · 12 of 12 weeks ahead Exact sum: 28.7 + 18.3 + 6.3 + 11.9 = 65.2 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 11. [FDC Ltd](https://www.sectoralpha.in/stocks/fdc-ltd) FDC · basing · Evidence leans up · 85% evidence 62.7 out of 100 Growth Capital Valuation Relative
12. [Corona Remedies Ltd](https://www.sectoralpha.in/stocks/corona-remedies-ltd) CORONA · turning · Evidence leans up · 73% evidence 62.3 out of 100 Growth Capital Valuation Relative
13. [Emcure Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/emcure-pharmaceuticals-ltd) EMCURE · losing its lead · Evidence leans up · 71% evidence 61.8 out of 100 Growth Capital Valuation Relative
14. [Mankind Pharma Ltd](https://www.sectoralpha.in/stocks/mankind-pharma-ltd) MANKIND · turning · Evidence leans up · 100% evidence 61.0 out of 100 Growth Capital Valuation Relative
15. [Zydus Lifesciences Ltd](https://www.sectoralpha.in/stocks/zydus-lifesciences-ltd) ZYDUSLIFE · leader · Evidence leans up · 96% evidence 59.5 out of 100 Growth Capital Valuation Relative
16. [ERIS Lifesciences Ltd](https://www.sectoralpha.in/stocks/eris-lifesciences-ltd) ERIS · basing · Evidence leans up · 67% evidence 56.1 out of 100 Growth Capital Valuation Relative
17. [Gufic BioSciences Ltd](https://www.sectoralpha.in/stocks/gufic-biosciences-ltd) GUFICBIO · leader · Evidence leans up · 71% evidence 56.0 out of 100 Growth Capital Valuation Relative
18. [Strides Pharma Science Ltd](https://www.sectoralpha.in/stocks/strides-pharma-science-ltd) STAR · breaking out · Evidence leans up · 75% evidence 55.3 out of 100 Growth Capital Valuation Relative
19. [Caplin Point Laboratories Ltd](https://www.sectoralpha.in/stocks/caplin-point-laboratories-ltd) CAPLIPOINT · losing its lead · Evidence leans up · 96% evidence 54.3 out of 100 Growth Capital Valuation Relative
20. [Wockhardt Ltd](https://www.sectoralpha.in/stocks/wockhardt-ltd) WOCKPHARMA · losing its lead · Evidence leans up · 71% evidence 52.9 out of 100 Growth Capital Valuation Relative
21. [Kilitch Drugs (India) Ltd](https://www.sectoralpha.in/stocks/kilitch-drugs-indialtd) KILITCH · breaking out · Evidence leans up · 78% evidence 51.3 out of 100 Growth Capital Valuation Relative
22. Akums Drugs & Pharmaceuticals Ltd this page AKUMS · leader · Evidence leans up · 71% evidence 50.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 13.5/35 · Revenue 9.2% · Profit -15.8% · Operating margin change 2 points · 83% evidence Capital efficiency 10.9/25 · ROCE 14.9% · Operating margin 15% · 76% evidence Valuation 9.8/20 · P/E 37.8× · PEG n/a · 15% evidence Relative strength 16.7/20 · Lead over its industry 9.6% · Lead over NIFTY 500 34.1% · 1 year 58.8% · 100% evidence · 12 of 12 weeks ahead Exact sum: 13.5 + 10.9 + 9.8 + 16.7 = 50.9 · What this means: Relative strength against the index is 34.1%, and revenue and profit growth are weak. 23. [Alembic Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/alembic-pharmaceuticals-ltd) APLLTD · turning · Evidence leans down · 81% evidence 47.9 out of 100 Growth Capital Valuation Relative
24. [Alkem Laboratories Ltd](https://www.sectoralpha.in/stocks/alkem-laboratories-ltd) ALKEM · quiet · Evidence leans down · 78% evidence 47.6 out of 100 Growth Capital Valuation Relative
25. [Bajaj Healthcare Ltd](https://www.sectoralpha.in/stocks/bajaj-healthcare-ltd) BAJAJHCARE · quiet · Evidence leans down · 100% evidence 46.6 out of 100 Growth Capital Valuation Relative
26. [Lincoln Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/lincoln-pharmaceuticals-ltd) LINCOLN · quiet · Evidence leans down · 100% evidence 45.9 out of 100 Growth Capital Valuation Relative
27. [Bharat Parenterals Ltd](https://www.sectoralpha.in/stocks/bharat-parenterals-ltd) BPLPHARMA · breaking out · Too little evidence to rank firmly · 52% evidence 45.9 out of 100 Growth Capital Valuation Relative
28. [Aurobindo Pharma Ltd](https://www.sectoralpha.in/stocks/aurobindo-pharma-ltd) AUROPHARMA · leader · Evidence leans down · 96% evidence 45.6 out of 100 Growth Capital Valuation Relative
29. [Amrutanjan Health Care Ltd](https://www.sectoralpha.in/stocks/amrutanjan-health-care-ltd) AMRUTANJAN · turning · Evidence leans down · 96% evidence 44.9 out of 100 Growth Capital Valuation Relative
30. [RPG Life Sciences Ltd](https://www.sectoralpha.in/stocks/rpg-life-sciences-ltd) RPGLIFE · losing its lead · Evidence leans down · 100% evidence 43.1 out of 100 Growth Capital Valuation Relative
31. [J B Chemicals & Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/j-b-chemicals-pharmaceuticals-ltd) JBCHEPHARM · Too little evidence to rank firmly · 59% evidence 42.4 out of 100 Growth Capital Valuation Relative
32. [Zim Laboratories Ltd](https://www.sectoralpha.in/stocks/zim-laboratories-ltd) ZIMLAB · leader · Evidence leans down · 71% evidence 40.7 out of 100 Growth Capital Valuation Relative
33. [Sun Pharmaceutical Industries Ltd](https://www.sectoralpha.in/stocks/sun-pharmaceutical-industries-ltd) SUNPHARMA · quiet · Evidence leans down · 100% evidence 39.3 out of 100 Growth Capital Valuation Relative
34. [Dr Reddys Laboratories Ltd](https://www.sectoralpha.in/stocks/dr-reddys-laboratories-ltd) DRREDDY · turning · Evidence leans down · 100% evidence 39.3 out of 100 Growth Capital Valuation Relative
35. [Natco Pharma Ltd](https://www.sectoralpha.in/stocks/natco-pharma-ltd) NATCOPHARM · quiet · Evidence leans down · 96% evidence 38.8 out of 100 Growth Capital Valuation Relative
36. [Bafna Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/bafna-pharmaceuticals-ltd) BAFNAPH · breaking out · Evidence leans down · 74% evidence 35.8 out of 100 Growth Capital Valuation Relative
37. [Cipla Ltd](https://www.sectoralpha.in/stocks/cipla-ltd) CIPLA · turning · Evidence leans down · 100% evidence 35.4 out of 100 Growth Capital Valuation Relative
38. [Torrent Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/torrent-pharmaceuticals-ltd) TORNTPHARM · losing its lead · Most evidence points down · 100% evidence 34.4 out of 100 Growth Capital Valuation Relative
39. [Biocon Ltd](https://www.sectoralpha.in/stocks/biocon-ltd) BIOCON · quiet · Most evidence points down · 96% evidence 33.6 out of 100 Growth Capital Valuation Relative
40. [Suven Life Sciences Ltd](https://www.sectoralpha.in/stocks/suven-life-sciences-ltd) SUVEN · quiet · Most evidence points down · 64% evidence 33.1 out of 100 Growth Capital Valuation Relative
41. [Influx Healthtech Ltd](https://www.sectoralpha.in/stocks/influx-healthtech-ltd) INFLUX · quiet · Too little evidence to rank firmly · 42% evidence 49.7 out of 100 Growth Capital Valuation Relative
42. [Syncom Healthcare Ltd](https://www.sectoralpha.in/stocks/syncom-healthcare-ltd) SYNCOM · Too little evidence to rank firmly · 17% evidence 42.3 out of 100 Growth Capital Valuation Relative
43. [Indoco Remedies Ltd](https://www.sectoralpha.in/stocks/indoco-remedies-ltd) INDOCO · losing its lead · Too little evidence to rank firmly · 49% evidence 38.4 out of 100 Growth Capital Valuation Relative
44. [Sai Parenterals Ltd](https://www.sectoralpha.in/stocks/sai-parenterals-ltd) SAIPARENT · turning · Too little evidence to rank firmly · 31% evidence 36.7 out of 100 Growth Capital Valuation Relative

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Pharma - Formulators](https://www.sectoralpha.in/sectors/pharma-formulators), all 44 compared on one page. ## Which companies are close to Akums Drugs & Pharmaceuticals in size? Akums Drugs & Pharmaceuticals is the 24th largest of 44 Pharma - Formulators companies on Sector Alpha by market value (scores of 30 October 2026). Just above it: Natco Pharma, Marksans Pharma and Corona Remedies. Just below it: Strides Pharma Science, Suven Life Sciences and Bliss GVS Pharma. ### Pharma - Formulators companies close in size

1. [Natco Pharma Ltd](https://www.sectoralpha.in/stocks/natco-pharma-ltd) ₹15,348 crore
2. [Marksans Pharma Ltd](https://www.sectoralpha.in/stocks/marksans-pharma-ltd) ₹13,876 crore
3. [Corona Remedies Ltd](https://www.sectoralpha.in/stocks/corona-remedies-ltd) ₹13,147 crore
4. Akums Drugs & Pharmaceuticals Ltd ₹11,517 crore
5. [Strides Pharma Science Ltd](https://www.sectoralpha.in/stocks/strides-pharma-science-ltd) ₹9,851 crore
6. [Suven Life Sciences Ltd](https://www.sectoralpha.in/stocks/suven-life-sciences-ltd) ₹7,314 crore
7. [Bliss GVS Pharma Ltd](https://www.sectoralpha.in/stocks/bliss-gvs-pharma-ltd) ₹6,888 crore

[All 44 Pharma - Formulators companies, largest first](https://www.sectoralpha.in/sectors/pharma-formulators#all-companies)

### Companies close in size in other industries

1. [Vedant Fashions Ltd](https://www.sectoralpha.in/stocks/vedant-fashions-ltd) ₹11,628 crore · Textiles - Readymade Apparel
2. [Canara HSBC Life Insurance Company Ltd](https://www.sectoralpha.in/stocks/canara-hsbc-life-insurance-company-ltd) ₹11,534 crore · Finance - Insurance
3. Akums Drugs & Pharmaceuticals Ltd ₹11,517 crore
4. [Edelweiss Financial Services Ltd](https://www.sectoralpha.in/stocks/edelweiss-financial-services-ltd) ₹11,474 crore · Finance & Investments - Wholesale NBFC
5. [Nuvoco Vistas Corporation Ltd](https://www.sectoralpha.in/stocks/nuvoco-vistas-corporation-ltd) ₹11,443 crore · Cement

## What else do people ask about Akums Drugs & Pharmaceuticals? ### What is Akums Drugs & Pharmaceuticals's share price today? Akums Drugs & Pharmaceuticals Ltd's share price is ₹751.50, +65.8% over the past year. The whole company is worth ₹11,824 Cr on the market. In the last 52 weeks it traded between ₹420 to ₹820; today it is 83% of the way up from the low, 16.8% above its 200-day average (as of 4 November 2026). ### What were Akums Drugs & Pharmaceuticals's latest quarterly results? Akums Drugs & Pharmaceuticals Ltd reported revenue of ₹1,167 Cr and net profit of ₹101 Cr for the Jun 2026 quarter. Revenue rose 14.0% and profit rose 55.4% compared with a year earlier. Earnings per share were ₹6.35 (as of 4 November 2026). ### What is Akums Drugs & Pharmaceuticals's market cap? Akums Drugs & Pharmaceuticals Ltd's market capitalisation is ₹11,824 Cr at a share price of ₹751.50. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 4 November 2026). ### How is Akums Drugs & Pharmaceuticals performing? Akums Drugs & Pharmaceuticals Ltd's share price has been rising for 28 weeks. In its latest quarter, revenue rose 14.0% and profit rose 55.4% compared with a year earlier. Over the past 13 weeks it has done better than the NIFTY 500, for 46 weeks running (as of 4 November 2026). ### Will Akums Drugs & Pharmaceuticals's share price go up? This page does not forecast Akums Drugs & Pharmaceuticals Ltd's share price. What it shows instead: the share price is ₹751.50, and it has been rising for 28 weeks. Its P/E of 38.8× is higher than 73% of its own last 2 years (as of 4 November 2026). ### Where is Akums Drugs & Pharmaceuticals in its business cycle? Akums Drugs & Pharmaceuticals Ltd's FY26 operating margin was 12.0%, against a 9-year range of −2.4% to 12.0%: the top of its range, a record year. When profit is at a record, every ratio looks better than usual, and the story depends on margins staying high. The latest quarter was 15.0%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 4 November 2026). ### What could break the Akums Drugs & Pharmaceuticals story? The main question: the share price moved +65.8% in a year while yearly earnings per share moved −24.6%. The difference came from the market paying a higher multiple. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 4 November 2026). ### Is Akums Drugs & Pharmaceuticals a stock worth studying right now? What the numbers show: Akums Drugs & Pharmaceuticals Ltd's share price has risen faster than its earnings: +65.8% in a year, against −24.6% for earnings per share. The main open question: whether earnings grow into a price that has already moved. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 4 November 2026). ### Is there a Akums Drugs & Pharmaceuticals share price forecast for 2026? What management itself guided: CDMO volume growth at least in the high teens in Q2; overall company volume growth at least double digit in coming quarters. ## Lists

- Momentum stocks: https://www.sectoralpha.in/momentum-stocks-india
- Pharma stocks: https://www.sectoralpha.in/sectors/pharma-stocks-india

This is research, not advice. We’re not SEBI-registered.